Cengiz Cinnioglu, PhD
Founder & CEO
Dr. Cengiz Cinnioglu is a Founder and CEO of Nextgen Genetics. He earned his PhD from Istanbul University, Turkey, in Forensic Science & Genetics. Dr. Cinnioglu began his career at the Hemogenetic department for Paternity Testing at Istanbul University Institute of Legal Medicine at Forensic Science & Genetics. He earned his undergraduate degree in Molecular Biology and Genetics.
Dr. Cinnioglu joined a pioneer research group led by Dr. Luca-Cavalli Sforza, who is a world-renowned geneticist, in tracking the genetic history of mankind at Stanford University in the Human Population Genetics Laboratory, as a collaborator for his PhD project. After completing his PhD, he continued to work in the same department as a post-doctoral fellow. His post doctoral research involves the molecular analysis of human DNA sequence variation in human populations and SNP’s discoveries on Y chromosomes.
After post doctorate fellowship he transitioned to Genetic Diagnosis on early human Embryo development with Fluorescence in situ hybridization (FISH) technique.
Dr. Cinnioglu joined Natera (Gene Security Network) in early 2007 to develop the first application in the world with new cutting edge microarray technology to screen all chromosomes on early human embryos. He has co-authored numerous patent applications during his research.
Dr. Cinnioglu has numerous peer-reviewed publications in respected scientific journals including Nature, American Journal Human Genetic, Human Genetics, Fertility and Sterility. He has presented at many national and international conferences.
Dr. Cinnioglu has a Laboratory Director License for Genetic Testing (Microarray for PGT-A), Cytogenetics, Andrology and Parentage/Identity testing from the New York State Department of Health. He is member of the American Society for Reproductive Medicine, The American Association of Bioanalysts and The Pre-implantation Genetic Diagnosis International Society.
Nextgen Genetics (NGG) is an advanced genetics facility operated by a team of Scientists and Geneticists. With the utilization of cutting-edge Next Generation Sequencing (NGS) platform NGG is committed to deliver the most accurate and reliable service to In Vitro Fertilization (IVF) field.
Nextgen Genetics is continuously developing innovative new technologies to meet the evolving needs of reproductive health genetics field.
Nextgen Genetics is advancing a pipeline of first-in-class biotech, including novel non-invasive pre-implantation genetic testing (niPGT-A) and targeted window of implantation (tWOI) to help infertile couples to have their healthy child in their first try.